TY - JOUR
T1 - Burden of Shigella among children with diarrhea in the Americas
T2 - A systematic review and meta-analysis
AU - Lubeck-Schricker, Maya
AU - Rivas-Nieto, Andrea C.
AU - Rosauer, Jennifer
AU - Mpinganjira, Samuel
AU - Malhotra, Akash
AU - Bastias, Magdalena
AU - McQuade, Elizabeth Rogawski
AU - Kosek, Margaret
AU - Lanata, Claudio F.
AU - Olortegui, Maribel Paredes
AU - Ochoa, Theresa J.
AU - Platts-Mills, James A.
AU - Vannice, Kirsten
AU - Pavlinac, Patricia B.
N1 - Publisher Copyright:
© 2025 Lubeck-Schricker et al.
PY - 2025/8
Y1 - 2025/8
N2 - Introduction Shigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting. Methods We conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present. Results This review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6-5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children <12 months was 1.0% (95% CI: 0.1 – 7.7) compared to 4.6% (95% CI: 1.2 – 15.4) for children ≥12 months. Conclusion Despite varying reporting practices, we found Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.
AB - Introduction Shigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting. Methods We conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present. Results This review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6-5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children <12 months was 1.0% (95% CI: 0.1 – 7.7) compared to 4.6% (95% CI: 1.2 – 15.4) for children ≥12 months. Conclusion Despite varying reporting practices, we found Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.
UR - https://www.scopus.com/pages/publications/105015721793
U2 - 10.1371/journal.pntd.0013393
DO - 10.1371/journal.pntd.0013393
M3 - Artículo
C2 - 40825034
AN - SCOPUS:105015721793
SN - 1935-2727
VL - 2025
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
M1 - e0013393
ER -